Cancer Discov. 2020 Dec;10(12):1781-1782. doi: 10.1158/2159-8290.CD-NB2020-095. Epub 2020 Oct 23.
Evidence continues to grow that KRAS, once considered an "undruggable" target, can be targeted successfully in non-small cell lung cancer. In a phase I trial, the KRAS inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.
越来越多的证据表明，KRAS 曾经被认为是一个“不可成药”的靶点，现在可以在非小细胞肺癌中成功靶向。在一项 I 期临床试验中，KRAS 抑制剂索托拉西布在大约三分之一的患者中引发了反应，且总体耐受性良好。
